Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells

20237 citationsJournal Articlegold Open Access

Authors

Marcos Quintela · Swansea University

David W. James · Swansea University

Agne Pociute · Swansea University

Lydia C. Powell · Swansea University

Kadie Edwards · Swansea University

Zoe Coombes · Swansea University

Jetzabel Garcia · Swansea University

Abstract

Overall, our ex vivo and in vitro studies indicate that i-BET858 represents an optimal candidate to pursue further clinical validation for the treatment of HGSC.

Topics & Keywords

Protein Degradation and Inhibitors Multiple Myeloma Research and Treatments Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Epigenetics

Volume 15, Issue 1, pp. 63-63

DOI: 10.1186/s13148-023-01477-x

Field-Weighted Citation Impact: 1.09